2022 07 15 19 56 0503 Genetics Dna Money 400

Danaher on Thursday announced second-quarter diagnostics revenues of $2.56 billion, up 9% compared to $2.34 billion in the prior-year quarter.

For the quarter ended July 1, the company said its overall revenues, including revenues for its diagnostics, life sciences, and environmental and applied solutions divisions, rose 7% year-over-year to $7.75 billion from $7.22 billion, well ahead of Wall Street analysts' average estimate of $7.3 billion.

The company posted Q2 net earnings of $1.68 billion, or $2.25 per share, compared to $1.79 billion, or $2.28 per share, in the prior-year quarter. Its Q2 adjusted EPS was $2.76, beating the analysts' average EPS estimate of $2.35.

Danaher shares were up more than 8% to $278.37 in afternoon trading on the New York Stock Exchange.

Page 1 of 9
Next Page